Incyte Total Cost of Revenue decreased by 13.7% to $104.52M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.8%, from $73.19M to $104.52M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 25.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $38.03M | $39.87M | $43.87M | $42.61M | $50.64M | $54.58M | $59.16M | $56.82M | $68.33M | $60.09M | $69.75M | $60.96M | $76.63M | $85.99M | $88.49M | $73.19M | $78.77M | $99.00M | $121.18M | $104.52M |
| QoQ Change | — | +4.8% | +10.0% | -2.9% | +18.8% | +7.8% | +8.4% | -4.0% | +20.2% | -12.1% | +16.1% | -12.6% | +25.7% | +12.2% | +2.9% | -17.3% | +7.6% | +25.7% | +22.4% | -13.7% |
| YoY Change | — | — | — | — | +33.2% | +36.9% | +34.8% | +33.3% | +34.9% | +10.1% | +17.9% | +7.3% | +12.2% | +43.1% | +26.9% | +20.1% | +2.8% | +15.1% | +36.9% | +42.8% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $73.19M | $78.77M | $99.00M | $121.18M | $104.52M |
| Total | $73.19M | $78.77M | $99.00M | $121.18M | $104.52M |